The CDK7-dependent transcriptional addition reported in MYCN-driven neuroblastoma [15], triple-negative breast cancer [16], and pancreatic cancer [33] is attractive because SE-associated genes are exceptionally inhibited by THZ1 so that targeting CDK7 is conducive to selective targeting. Here, CDK7 is linked to triple-negative breast carcinoma.